PCSK9 and acute coronary syndrome: Cardiovascular risk OR myocardial infarction OR acute coronary syndrome OR ("myocardial infarction/drug therapy"[Majr] OR "myocardial infarction/mortality"[Majr] OR "myocardial infarction/prevention and control"[Majr]) AND PCSK9 inhibitors OR evolocumab OR alirocumab OR ("PCSK9 inhibitors/pharmacology"[Majr] OR "PCSK9 inhibitors/therapeutic use"[Majr])